Cancer and immunomodulators in inflammatory bowel diseases

Inflammatory Bowel Diseases

Volumn 21, Issue 3, 2015, Pages 674-688

  Biancone, Livia ^a   Onali, Sara ^a   Petruzziello, Carmelina ^a   Calabrese, Emma ^a   Pallone, Francesco ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

hematologic malignancies; immunomodulators; inflammatory bowel disease; solid tumors

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; GOLIMUMAB; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; IMMUNOLOGIC FACTOR;

ARTICLE; BILE DUCT CARCINOMA; CANCER RISK; CANCER SURVIVAL; COCHRANE LIBRARY; CROHN DISEASE; DIGESTIVE SYSTEM CANCER; EMBASE; HEMATOLOGIC MALIGNANCY; HUMAN; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MEDLINE; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PERIPHERAL T CELL LYMPHOMA; PRIMARY INTESTINAL LYMPHOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; SKIN CANCER; SOLID TUMOR; ULCERATIVE COLITIS; ANIMAL; CHEMICALLY INDUCED; COMPLICATION; INFLAMMATORY BOWEL DISEASES; NEOPLASM; RISK FACTOR;

ANIMALS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; NEOPLASMS; RISK FACTORS;

EID: 84923394018     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000243     Document Type: Article

References (94)

1. Van Assche G, Dignass A, Panes J, et al. The second European evidencebased consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. J Crohns Colitis. 2010; 4: 7-27.
2. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology. 2011; 140: 1807-1816.
3. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a key factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004; 126: 451-459.
4. Popivanova BK, Kitamura K, Wu Y, et al. Blocking TNF-A in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest. 2008; 118: 560-570.
5. Jess T, Winther KV, Munkholm P, et al. Intestinal and extra-intestinal cancer in Crohn's disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther. 2004; 19: 287-293.
6. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, et al. Long-term complications, extraintestinal manifestations, and mortality in adult Crohn's disease in population-based cohorts. Inflamm Bowel Dis. 2011; 17: 471-478.
7. Peyrin-Biroulet L, Lepage C, Jooste V, et al. Colorectal cancer in inflammatory bowel diseases: a population-based study (1976-2008). Inflamm Bowel Dis. 2012; 18: 2247-2251.
8. Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-Analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2012; 10: 639-645.
9. Herrinton LJ, Liu L, Levin TR, et al. Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology. 2012; 143: 382-389.
10. Jess T, Simonsen J, Jørgensen KT, et al. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012; 143: 375-381.
11. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-Aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005; 100: 1345-1353.
12. Beaugerie L, Svrcek M, Seksik P, et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology. 2013; 145: 166-175.
13. Elriz K, Carrat F, Carbonnel F, et al. Incidence, presentation, and prognosis of small bowel adenocarcinoma in patients with small bowel Crohn's disease: a prospective observational study. Inflamm Bowel Dis. 2013; 19: 1823-1826.
14. Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012; 143: 390-399.
15. Pedersen N, Duricova D, Elkjaer M, et al. Risk of extra-intestinal cancer in inflammatory bowel disease: meta-Analysis of population-based cohort studies. Am J Gastroenterol. 2010; 105: 1480-1487.
16. Benjelloun el B, Abkari M, Ousadden A, et al. Squamous cell carcinoma associated anal fistulas in Crohn's disease unique case report with literature review. J Crohns Colitis. 2013; 7: 232-235.
17. Biancone L, Zuzzi S, Ranieri M, et al. Fistulizing pattern in Crohn's disease and pancolitis in ulcerative colitis are independent risk factors for cancer: a single-center cohort study. J Crohns Colitis. 2012; 6: 578-587.
18. Jess T, Horváth-Puhó E, Fallingborg J, et al. Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study. Am J Gastroenterol. 2013; 108: 1869-1876.
19. Kappelman MD, Farkas DK, Long MD, et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol. 2014; 12: 265-273.
20. Kim SC, Glynn RJ, Giovannucci E, et al. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Ann Rheum Dis. [published online ahead of print March 11, 2014]. doi: 10.1136/annrheumdis-2013-204993.
21. Magro F, Peyrin-Biroulet L, Sokol H, et al. Extra-intestinal malignancies in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (III). J Crohns Colitis. 2014; 8: 31-44.
22. Ananthakrishnan AN, Cagan A, Gainer VS, et al. Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease. J Crohns Colitis. 2014; 8: 956-963.
23. Greenstein AJ, Gennuso R, Sachar D, et al. Extraintestinal cancer in inflammatory bowel disease. Cancer. 1985; 15; 2914-2921.
24. Hanauer SB, Wong KK, Frank PH, et al. Acute leukemia following inflammatory bowel disease. Dig Dis Sci. 1982; 27: 545-548.
25. Glick SN, Teplick SK, Goodman LR, et al. Development of lymphoma in patients with Crohn disease. Radiology. 1984; 153: 337-339.
26. Sataline LR, Mobley EM, Kirkham W. Ulcerative colitis complicated by colonic lymphoma. Gastroenterology. 1963; 44: 342-347.
27. Sokol H, Beaugerie L, Maynadié M, et al. Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012; 18: 2063-2071.
28. Connell WR, Kamm MA, Dickson M, et al. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet. 1994; 343: 1249-1252.
29. Korelitz BI, Mirsky FJ, Fleisher MR, et al. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol. 1999; 94: 3248-3253.
30. Farrell RJ, Ang Y, Kileen P, et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut. 2000; 47: 514-519.
31. Fraser AG, Orchard TR, Robinson EM, et al. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther. 2002; 16: 1225-1232.
32. van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995; 109: 129-135.
33. Fiocchi C. Closing fistulas in Crohn's disease-should the accent be on maintenance or safety. N Engl J Med. 2004; 350: 934-946.
34. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004; 350: 876-885.
35. Biancone L, Orlando A, Kohn A, et al. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut. 2006; 55: 228-233.
36. Biancone L, Petruzziello C, Orlando A, et al. Cancer in Crohn's disease patients treated with infliximab: a long-term multicenter matched pair study. Inflamm Bowel Dis. 2011; 17: 758-766.
37. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006; 4: 621-630.
38. Bhatia J, Bratcher J, Korelitz B, et al. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J Gastroenterol. 2006; 12: 6167-6171.
39. Biancone L, Calabrese E, Petruzziello C, et al. Treatment with biologic therapies and the risk of cancer in patients with IBD. Nat Clin Pract Gastroenterol Hepatol. 2007; 4: 78-91.
40. Masunaga Y, Ohno K, Ogawa R, et al. Meta-Analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann Pharmacother. 2007; 41 21-28.
41. Caspersen S, Elkjaer M, Riis L, et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol. 2008; 6: 1212-1217.
42. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-Analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008; 6: 644-653.
43. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gastroenterol. 2008; 103: 631-636.
44. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009; 58: 501-508.
45. Petruzziello C, Calabrese E, Zorzi F, et al. Long-term safety of Infliximab for the treatment of inflammatory bowel disease: does blocking TNFalpha reduce colitis-Associated colorectal carcinogenesis. Gut. 2009; 58: 1703.
46. McKenzie SM, Doe WF, Buffinton GD. 5-Aminosalicylic acid prevents oxidant mediated damage of glyceraldehyde-3-phosphate dehydrogenase in colon epithelial cells. Gut. 1999; 44: 180-185.
47. Singh H, Demers AA, Nugent Z, et al. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested casecontrol study. Gastroenterology. 2009; 136: 451-458.
48. Armstrong RG, West J, Card TR. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol. 2010; 105: 1604-1609.
49. Long MD, Herfarth HH, Pipkin C, et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010; 8: 268-274.
50. Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011; 9: 30-35.
51. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011; 141: 1621-1628.
52. Singh H, Nugent Z, Demers AA, et al. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology. 2011; 141: 1612-1620.
53. Van Schaik FDM, Vam Oijen MGH, Smeets UG, et al. Risk of nonmelanoma skin cancer in patients with inflammatory bowel disease who use thiopurines is not increased. Clin Gastroenterol Hepatol. 2011; 9: 449-450.
54. Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximab-And immunomodulatortreated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012; 107: 1051-1063.
55. Pasternak B, Svanström H, Schmiegelow K, et al. Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol. 2013; 177: 1296-1305.
56. Williams CJ, Peyrin-Biroulet L, Ford AC. Systematic review with metaanalysis: malignancies with anti-tumour necrosis factor-A therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2014; 39: 447-458.
57. Lichtenstein GR, Feagan BG, Cohen RD, et al. Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry. Am J Gastroenterol. 2014; 109: 212-223.
58. Ariyaratnam J, Subramanian V. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-Analysis. Am J Gastroenterol. 2014; 109: 163-169.
59. Osterman MT, Sandborn WJ, Colombel JF, et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology. 2014; 146: 941-949.
60. Singh S, Nagpal SJ, Murad MH, et al. Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-Analysis. Clin Gastroenterol Hepatol. 2014; 12: 210-218.
61. Terdiman JP, Gruss CB, Heidelbaugh JJ. American gastroenterological association Institute guideline on the Use of thiopurines, methotrexate, and Anti-TNF-A biologic drugs for the Induction and maintenance of remission in inflammatory Crohn's disease. Gastroenterology. 2014; 145: 1459-1463.
62. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short-And long-term toxicity. Ann Intern Med. 1989; 111: 641-649.
63. Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology. 2000; 118: 1018-1024.
64. Lewis JD, Bilker WB, Brensinger C, et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 2001; 121: 1080-1087.
65. Freeman HJ. Tabulation of myeloid, lymphoid and intestinal malignancies in Crohn's disease. Can J Gastroenterol. 2002; 16: 779-784.
66. Dayharsh GA, Loftus EV Jr, SandbornWJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology. 2002; 122: 72-77.
67. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005; 54: 1121-1125.
68. Siegel CA, Hur C, Korzenik JR, et al. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol. 2006; 4: 1017-1024.
69. Afif W, Sandborn WJ, Faubion WA, et al. Risk factors for lymphoma in patients with inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2013; 19: 1384-1389.
70. Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-Analysis. Clin Gastroenterol Hepatol. 2009; 7: 874-881.
71. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009; 374: 1617-1625.
72. Sokol H, Beaugerie L Inflammatory bowel disease and lymphoproliferative disorders: the dust is starting to settle. Gut. 2009; 58: 1427-1436.
73. Herrinton LJ, Liu L, Weng X, et al. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2011; 106: 2146-2153.
74. Siegel CA, Finlayson SR, Sands BE, et al. Adverse events do not outweigh benefits of combination therapy for Crohn's disease in a decision analytic model. Clin Gastroenterol Hepatol. 2012; 10: 46-51.
75. Siegel CA, Mason M, Siegel CA. Do inflammatory bowel disease therapies cause cancer. Inflamm Bowel Dis. 2013; 19: 1306-1321.
76. Khan N, Abbas AM, Lichtenstein GR, et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines: a nationwide retrospective cohort study. Gastroenterology. 2013; 145: 1007-1015.
77. Biancone L, Petruzziello C, Armuzzi A, et al. Characterization of incident cases of cancer in inflammatory bowel disease: a prospective multicenter matched-pair IG-IBD study. Gastroenterology. 2014; 146: S-448. Abstract.
78. Lakatos PL, Lovasz BD, David G, et al. The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: results froma population-based cohort in Eastern Europe. J Crohns Colitis. 2013; 7: 385-391.
79. Lopez A, Mounier M, Bouvier AM, et al. Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2014; 12: 1324-1329.
80. Kotlyar DS, Lewis JD, Beaugerie L, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-Mercaptopurine: a meta-Analysis. Clin Gastroenterol Hepatol. [published online ahead of print May 28, 2014]. doi: 10.1016/j.cgh.2014.05.015.
81. Falchook GS, Vega F, Dang NH, et al. Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. Ann Oncol. 2009; 20: 1080-1085.
82. Mackey AC, Green L, Leptak C, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007; 44: 265-267.
83. Thai A, Prindiville T. Hepatosplenic T-cell lymphoma and inflammatory bowel disease. J Crohns Colitis. 2010; 4: 511-522.
84. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011; 9: 36-41.
85. Selvaraj SA, Chairez E, Wilson LM, et al. Use of case reports and the adverse event reporting system in systematic reviews: overcoming barriers to assess the link between Crohn's disease medications and hepatosplenic T-cell lymphoma. Syst Rev. 2013; 5: 53.
86. Beaugerie L, Carrat F, Colombel JF, et al. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut. 2013. doi: 10.1136/gutjnl-20.
87. Beaugerie L. Use of immunosuppressants and biologicals in patients with previous cancer. Dig Dis. 2013; 31: 254-259.
88. Gong J, Zhu L, Guo Z, et al. Use of thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel diseases: a meta-Analysis. PLoS One. 2013; 8: e81487.
89. Rubin DT, Huo D, Kinnucan JA, et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a casecontrol study. Clin Gastroenterol Hepatol. 2013; 11: 1601-1608.
90. Van Assche G, Lewis JD, Lichtenstein GR, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response. Am J Gastroenterol. 2011; 106: 199-212.
91. Clark M, Colombel JF, Feagan BC, et al. American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21 to 23, 2006. Gastroenterology. 2007; 133: 312-339.
92. Orlando A, Armuzzi A, Papi C, et al. The use of tumor necrosis factoralpha antagonist therapy in inflammatory bowel disease. Dig Liver Dis. 2011; 43: 1-20.
93. Sebastian S, Hernández V, Myrelid P, et al. Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I). J Crohns Colitis. 2014; 8: 5-18.
94. Egan L, D'Inca R, Jess T, et al. Non-colorectal intestinal tract carcinomas in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (II). J Crohns Colitis. 2014; 8: 19-30.